This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Durand-Zaleski, I. Articles by Rostoker, G. Search for Related Content PubMed PubMed Citation Articles by Durand-Zaleski, I. Articles by Rostoker, G. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

A Cost Analysis of the Prevention of End-stage Renal Disease

Immunoglobulin Therapy for IgA Nephropathy

Sylvie Bastuji-Garin, MD

Stéphane Zaleski, PhD

Bertrand Weil, MD

Guy Rostoker, MD, PhD

A cost analysis was used to evaluate three possible immunoglobulin (IgG) treatment protocols for end-stage renal disease due to IgA nephropathy. The perspective chosen for the cost analysis was that of the health-care delivery system. The baseline strategy was the absence of IgG treatment, and alternative strategies corresponded to three protocols presently on trial: all three included a high initial dose of intravenous IgG. Protocol 1 followed with intramuscular IgG injections only, protocol 2 with intramuscular plus intravenous injections, and protocol 3 with intravenous injections only. The costs of treatment included the costs of immunoglobulins, outpatient hospital costs, and the costs of tests; the savings (costs averted) resulted from kidney dialysis averted. The bottom line for the health-care system is a net savings of $233,000, $213,000, or $83,000, depending on the protocol chosen. The computation of costs did not value physical and psychological health benefits. Thus, any subjective benefit, such as im proved comfort, or objective benefit, such as longer life expectancy, would be an im provement over the results presented here. Key words: cost analysis; end-stage renal disease; treatment protocols. (Med Decis Making 1996;16:326-334)

Medical Decision Making, Vol. 16, No. 4, 326-334 (1996)
DOI: 10.1177/0272989X9601600403


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. A. Sonnenberg Immunoglobulin Therapy for IgA Nephropathy: When Is Cost Saving Enough? Med Decis Making, October 1, 1996; 16(4): 420 - 421. [PDF]